uniQure upgraded to Strong Buy at Raymond James after FDA alignment reached

Raymond James upgraded uniQure (QURE) to Strong Buy from Outperform with a price target of $52, up from $20, after uniQure revealed that they received alignment from the FDA on an accelerated approval filing of AMT-130 for Huntington’s Disease. Importantly, no additional clinical studies will be required to support the BLA submission. Based on today’s update, the firm expects a BLA filing of AMT-130 in 2025 and is “confident” that the existing composite Unified Huntington Disease Rating Scale data will support an accelerated approval, says the analyst, who believes the Huntington’s opportunity in the U.S. alone could be greater than $2B.